Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Interim Results Date

9th Jan 2014 07:00

RNS Number : 2220X
Clinigen Group plc
09 January 2014
 

 

Clinigen Group plc

Notification of Interim Results Date

Burton-on-Trent, UK - 9 January 2014 - Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its interim results for the six months ended 31 December 2013 on Wednesday, 26 February 2014.

A group analyst briefing will be held at 09:30am GMT on Wednesday, 26 February 2014 at the Group's London offices at 1 King Street, London EC2V 8AU. Analysts who wish to participate should contact College Hill on +44 (0)20 7457 2020 or email [email protected] to register.

- Ends -

Contact Details

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer

Robin Sibson, Group Chief Financial Officer

Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

Michael Meade/Freddie Barnfield (Nominated Adviser)

James Black/Tom Ballard (Corporate Broking)

Peel Hunt LLP - Joint Broker

Tel: +44 (0) 20 7418 8900

James Steel / Jock Maxwell Macdonald

College Hill

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell/ Stefanie Bacher

Email: [email protected]

About Clinigen Group

The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering 'the right drug, to the right patient at the right time', has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of global access programs for biotechnology and pharmaceutical companies.

For more information, please visit www.clinigengroup.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORUGUAUGUPCGQR

Related Shares:

CLIN.L
FTSE 100 Latest
Value8,417.34
Change2.09